Approaches to gene therapy with sodium/iodide symporter

C. Spitzweg, J. C. Morris

Research output: Contribution to journalShort survey

20 Citations (Scopus)

Abstract

Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.

Original languageEnglish (US)
Pages (from-to)56-59
Number of pages4
JournalExperimental and Clinical Endocrinology and Diabetes
Volume109
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Genetic Therapy
Genes
Prostatic Neoplasms
Neoplasms
Iodides
Organism Cloning
Prostate
Therapeutics
Research Personnel
sodium-iodide symporter
Cell Line
In Vitro Techniques

Keywords

  • Gene therapy
  • Prostate cancer
  • Sodium/iodide symporter (NIS)

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Approaches to gene therapy with sodium/iodide symporter. / Spitzweg, C.; Morris, J. C.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 109, No. 1, 2001, p. 56-59.

Research output: Contribution to journalShort survey

Spitzweg, C. ; Morris, J. C. / Approaches to gene therapy with sodium/iodide symporter. In: Experimental and Clinical Endocrinology and Diabetes. 2001 ; Vol. 109, No. 1. pp. 56-59.
@article{8fe2186262d5407ebd815a3d5dcf5f84,
title = "Approaches to gene therapy with sodium/iodide symporter",
abstract = "Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.",
keywords = "Gene therapy, Prostate cancer, Sodium/iodide symporter (NIS)",
author = "C. Spitzweg and Morris, {J. C.}",
year = "2001",
doi = "10.1055/s-2001-11020",
language = "English (US)",
volume = "109",
pages = "56--59",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "1",

}

TY - JOUR

T1 - Approaches to gene therapy with sodium/iodide symporter

AU - Spitzweg, C.

AU - Morris, J. C.

PY - 2001

Y1 - 2001

N2 - Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.

AB - Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.

KW - Gene therapy

KW - Prostate cancer

KW - Sodium/iodide symporter (NIS)

UR - http://www.scopus.com/inward/record.url?scp=0035126384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035126384&partnerID=8YFLogxK

U2 - 10.1055/s-2001-11020

DO - 10.1055/s-2001-11020

M3 - Short survey

VL - 109

SP - 56

EP - 59

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 1

ER -